Aromasin
Advance Directives, Postmenopause, Breast + 1 more
Treatment
5 FDA approvals
15 Active Studies for Aromasin
Treatment for
Advance Directives
What is Aromasin
Exemestane
The Generic name of this drug
Treatment Summary
Exemestane is a pill that helps treat hormone-receptor-positive breast cancer in postmenopausal women. It works by blocking the aromatase enzyme from converting other hormones into estrogen. This prevents the cancer cells from using estrogen and stops the growth of the tumor.
Aromasin
is the brand name
Aromasin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Aromasin
Exemestane
1999
18
Approved as Treatment by the FDA
Exemestane, also known as Aromasin, is approved by the FDA for 5 uses which include Early Breast Cancer and 2-3 years of tamoxifen therapy .
Early Breast Cancer
2-3 years of tamoxifen therapy
Postmenopause
Breast
Advance Directives
Effectiveness
How Aromasin Affects Patients
Aromatase inhibitors (AIs) are drugs that limit the amount of the hormone estrogen in the body by blocking the action of the enzyme aromatase. Selective AIs (SAIs) target just estrogen and leave other hormones produced by the adrenal glands alone. Examples of SAIs include anastrozole, letrozole, and exemestane.
How Aromasin works in the body
Exemestane is used to treat postmenopausal breast cancer. It works by blocking an enzyme called aromatase, which converts androgens to estrogens. Estrogen encourages the growth of some breast cancer cells, so blocking it can reduce the growth of cancer cells. Exemestane binds to the active site of the aromatase enzyme, which prevents it from working and reduces estrogen levels. Exemestane does not affect other enzymes in the body, and does not interfere with the production of corticosteroids or aldosterone. Reducing the amount of estrogen in the body can slow down tumor growth and help stop
When to interrupt dosage
The measure of Aromasin depends on the diagnosed condition, such as 2-3 years of tamoxifen therapy, Advance Directives and Breast. The amount of dosage is contingent upon the technique of delivery (e.g. Tablet - Oral or Tablet, film coated) noted in the table underneath.
Condition
Dosage
Administration
Advance Directives
, 25.0 mg
, Oral, Tablet - Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral
Postmenopause
, 25.0 mg
, Oral, Tablet - Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral
Breast
, 25.0 mg
, Oral, Tablet - Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral
2-3 years of tamoxifen therapy
, 25.0 mg
, Oral, Tablet - Oral, Tablet, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral
Warnings
There are 3 known major drug interactions with Aromasin.
Common Aromasin Drug Interactions
Drug Name
Risk Level
Description
Haloperidol
Moderate
The serum concentration of Haloperidol can be increased when it is combined with Exemestane.
Methadone
Moderate
The serum concentration of Methadone can be increased when it is combined with Exemestane.
Tucatinib
Moderate
The metabolism of Tucatinib can be decreased when combined with Exemestane.
Aromasin Toxicity & Overdose Risk
Seizures
Aromasin Novel Uses: Which Conditions Have a Clinical Trial Featuring Aromasin?
Currently, there are 20 active studies investigating the potential of Aromasin to provide Advance Directives, 2-3 years of tamoxifen therapy and Postmenopausal relief.
Condition
Clinical Trials
Trial Phases
Advance Directives
0 Actively Recruiting
2-3 years of tamoxifen therapy
0 Actively Recruiting
Breast
10 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 4
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Aromasin Reviews: What are patients saying about Aromasin?
5
Patient Review
3/19/2022
Aromasin for Advanced Breast Cancer Progression Post-Antiestrogen Therapy
4
Patient Review
6/8/2014
Aromasin for Hormone Receptor Positive Postmenopausal Early Breast Cancer After Adjuvant Tamoxifen
2.7
Patient Review
4/26/2016
Aromasin for Hormone Receptor Positive Postmenopausal Early Breast Cancer After Adjuvant Tamoxifen
2.3
Patient Review
7/13/2017
Aromasin for Prevention of Breast Cancer
2.3
Patient Review
10/31/2018
Aromasin for Hormone Receptor Positive Postmenopausal Early Breast Cancer After Adjuvant Tamoxifen
1.3
Patient Review
2/4/2016
Aromasin for Hormone Receptor Positive Postmenopausal Early Breast Cancer After Adjuvant Tamoxifen
1
Patient Review
5/12/2015
Aromasin for Hormone Receptor Positive Postmenopausal Early Breast Cancer After Adjuvant Tamoxifen
1
Patient Review
1/25/2016
Aromasin for Hormone Receptor Positive Postmenopausal Early Breast Cancer After Adjuvant Tamoxifen
1
Patient Review
3/13/2016
Aromasin for Advanced Breast Cancer Progression Post-Antiestrogen Therapy
Patient Q&A Section about aromasin
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is Aromasin a chemotherapy drug?
"Aromasin is used to treat breast cancer in postmenopausal women. It is often given to women whose cancer has progressed even after taking tamoxifen for 2 to 3 years."
Answered by AI
How does Aromasin make you feel?
"Exemestane may make you feel nauseous or cause vomiting, but these symptoms generally improve over time."
Answered by AI
What does Aromasin do to the body?
"Aromasin prevents the enzyme aromatase from converting androgen into estrogen, thus reducing the amount of estrogen available to stimulate the growth of hormone receptor-positive breast cancer cells."
Answered by AI
Is Aromasin an estrogen blocker?
"Aromasin is a type of endocrine therapy that inhibits the aromatase enzyme. This lowers the level of the hormone estrogen in the body, which can starved cancer cells of their growth fuel. Aromasin is a pill that is taken orally."
Answered by AI